PR Newswire
MONROVIA, Calif., May 17, 2016
MONROVIA, Calif., May 17, 2016 /PRNewswire/ -- Xencor,
Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the
treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil
Dahiyat, president and chief executive officer, will present a corporate overview at two upcoming conferences:
- UBS Global Healthcare Conference
Date: Tuesday, May 24, 2016
Time: 11:30 a.m. ET
Location: New York, NY
- Jefferies 2016 Healthcare Conference
Date: Tuesday, June 7, 2016
Time: 11:00 a.m. ET
Location: New York, NY
Live webcasts of both events will be available on the "Events & Presentations" section in the Investors section of the
Company's website located at http://investors.xencor.com/events.cfm. A replay of the presentations will be posted on the Xencor website
approximately one hour after the live events and will be available for 30 days following the presentations.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of
autoimmune diseases, asthma and allergic diseases and cancer. Currently, nine candidates that have been engineered
with Xencor's XmAb® technology are in clinical development internally and with
partners. Xencor's internally-discovered programs include: XmAb5871 in Phase 2 development for the treatment of
IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb7195 in Phase 1a development for the
treatment of asthma and allergic diseases; and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical
trials for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering
technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic
action. Xencor partners include Amgen, Merck, Janssen R&D LLC, Alexion, Novo Nordisk and Boehringer
Ingelheim. For more information, please visit www.xencor.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xencor-to-present-at-upcoming-investor-conferences-300269291.html
SOURCE Xencor, Inc.